Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP)

Abstract

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of eltrombopag for the treatment of adults with chronic idiopathic (immune) thrombocytopenic purpura (ITP), based on a review of the manufacturer's submission (MS) to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process. ITP is an autoimmune disorder by …

Authors

Boyers D; Jia X; Crowther M; Jenkinson D; Fraser C; Mowatt G

Journal

Health Technology Assessment, Vol. 15, No. Suppl 1 Article 3, pp. 23–32

Publisher

National Institute for Health and Care Research

Publication Date

5 2011

DOI

10.3310/hta15suppl1/03

ISSN

1366-5278

Associated Experts

Mark Crowther

Professor, Faculty of Health Sciences

Visit profile

Labels